Hikma, GB00B128J450

Hikma stock pre-market at EUR 0.86: minus 1.15 percent

Published on 10/01/2026 at 08:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hikma stock was at EUR 0.86 pre-market at 8:33 a.m. CEST on October 1, 2026, according to Lang & Schwarz. That was minus 1.15 percent versus the EUR 0.87 prior close.

Fotorealistische sterile Pharma-Produktionslinie mit Injektionsfläschchen und Edelstahlanlagen
Hikma Pharmaceuticals PLC GB00B128J450 zeigt moderne Injektions-Produktionslinie in sterilem Pharmawerk mit Edelstahlanlagen, Illustration mit AI erstellt.

Hikma stock was at EUR 0.86 pre-market at 8:33 a.m. CEST on October 1, 2026, according to Lang & Schwarz. The price was minus 1.15 percent versus the EUR 0.87 prior close on September 30, 2026.

Pre-market price

Lang & Schwarz showed a bid of EUR 0.85 and an ask of EUR 0.88 alongside the pre-market price. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Hikma stock.

New chief financial officer

In a September 24, 2026 press release, Hikma said Rebecca Hall will become chief financial officer and executive director in the first quarter of 2027. She will replace Khalid Nabilsi, who is scheduled to step down from the board on December 31, 2026. Areb Kurdi will remain acting CFO until Hall joins.

R&D investor seminars

In a September 22, 2026 company announcement distributed through RNS, Hikma said it aspires to spend around 5 percent to 6 percent of revenue on research and development. The company scheduled investor seminars for October 20, November 24 and December 16, 2026, and said its next scheduled trading update is November 5, 2026.

Disclaimer...

en | GB00B128J450 | HIKMA | boerse | 70208493 | bgmi